ASH 2022: China Biotechs Showcase Latest Clinical Trial Results
The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New...
Cancer
RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers
China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained...
Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022
China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the...
Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199
Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based...
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...
Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech
Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and...
Jacobio’s KRAS G12C Inhibitor JAB-21822 Receives Breakthrough Therapy Designation
The Center for Drug Evaluation (CDE) website indicates that China-based Jacobio Pharmaceuticals Group Co., Ltd’s...
Yuanmai Cell Biotechnology Secures Angel Funding for Macrophage Immunotherapy
Yuanmai Cell Biotechnology Co., Ltd, a macrophage immunotherapy developer based in Nanjing, reportedly raised “tens...
SciClone’s Danyelza Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that SciClone Pharmaceuticals Inc’s (Nasdaq: SCLN) Danyelza...
Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study
AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) released the latest data supporting the...
Westgene Biopharma Secures RMB 150M Series A Financing for mRNA Drug Development
Westgene Biopharma, an mRNA drug developer based in Chengdu, reportedly raised RMB 150 million (USD...
Hainan’s First Integrated Bladder Cancer Center Launched at Provincial Urology Meeting
The first Integrated Bladder Cancer Center (IBCC) in Hainan province was inaugurated in Hainan General...
Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...
Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I...
Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia
A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...
Hansoh’s EGFR Inhibitor Ameile Filed for EMA Review by Partner EQRx
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a market filing for its...
Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...
Yifan Pharma Transfers F-627 Distribution Rights in Germany to Apogepha
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the transfer of exclusive distribution rights in...
Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials
China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval...
Eli Lilly Ends License for Innovent’s Tyvyt Outside China
Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...